|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Loibl S and Gianni L: HER2-positive breast
cancer. Lancet. 389:2415–2429. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wang Q, Li J, Zheng S, Li JY, Pang Y,
Huang R, Zhang BN, Zhang B, Yang HJ, Xie XM, et al: Breast cancer
stage at diagnosis and area-based socioeconomic status: A
multicenter 10-year retrospective clinical epidemiological study in
China. BMC Cancer. 12:1222012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Heinemann V, Di Gioia D, Vehling-Kaiser U,
Harich HD, Heinrich B, Welt A, Ziske C, Deutsch G, Pihusch R, Kölbl
H, et al: A prospective multicenter phase II study of oral and i.v.
vinorelbine plus trastuzumab as first-line therapy in
HER2-overexpressing metastatic breast cancer. Ann Oncol.
22:603–608. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Cameron D, Piccart-Gebhart MJ, Gelber RD,
Procter M, Goldhirsch A, de Azambuja E, Castro G Jr, Untch M, Smith
I, Gianni L, et al: 11 years' follow-up of trastuzumab after
adjuvant chemotherapy in HER2-positive early breast cancer: Final
analysis of the HERceptin Adjuvant (HERA) trial. Lancet.
389:1195–1205. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chen X, Wang J, Fan Y, Luo Y, Zhang P, Li
Q, Ma F, Yuan P, Chen S, Li Q, et al: Primary trastuzumab
resistance after (Neo)adjuvant Trastuzumab-containing treatment for
patients with HER2-positive breast cancer in real-world practice.
Clin Breast Cancer. 21:191–198. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Viallard C and Larrivee B: Tumor
angiogenesis and vascular normalization: Alternative therapeutic
targets. Angiogenesis. 20:409–426. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Banerjee S, Dowsett M, Ashworth A and
Martin LA: Mechanisms of disease: angiogenesis and the management
of breast cancer. Nat Clin Pract Oncol. 4:536–550. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhou Y, Ren X, Hou Z, Wang N, Jiang Y and
Luan Y: Engineering a photosensitizer nanoplatform for amplified
photodynamic immunotherapy via tumor microenvironment modulation.
Nanoscale Horiz. 6:120–131. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Miller K, Wang M, Gralow J, Dickler M,
Cobleigh M, Perez EA, Shenkier T, Cella D and Davidson NE:
Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic
breast cancer. N Engl J Med. 357:2666–2676. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Robert NJ, Diéras V, Glaspy J, Brufsky AM,
Bondarenko I, Lipatov ON, Perez EA, Yardley DA, Chan SY, Zhou X, et
al: RIBBON-1: Randomized, double-blind, placebo-controlled, phase
III trial of chemotherapy with or without bevacizumab for
first-line treatment of human epidermal growth factor receptor
2-negative, locally recurrent or metastatic breast cancer. J Clin
Oncol. 29:1252–1260. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Brufsky AM, Hurvitz S, Perez E, Swamy R,
Valero V, O'Neill V and Rugo HS: RIBBON-2: A randomized,
double-blind, placebo-controlled, phase III trial evaluating the
efficacy and safety of bevacizumab in combination with chemotherapy
for second-line treatment of human epidermal growth factor receptor
2-negative metastatic breast cancer. J Clin Oncol. 29:4286–4293.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Cobleigh MA, Langmuir VK, Sledge GW,
Miller KD, Haney L, Novotny WF, Reimann JD and Vassel A: A phase
I/II dose-escalation trial of bevacizumab in previously treated
metastatic breast cancer. Semin Oncol. 30:117–124. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Baselga J, Segalla JG, Roché H, Del Giglio
A, Pinczowski H, Ciruelos EM, Filho SC, Gómez P, Van Eyll B,
Bermejo B, et al: Sorafenib in combination with capecitabine: An
oral regimen for patients with HER2-negative locally advanced or
metastatic breast cancer. J Clin Oncol. 30:1484–1491. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Burstein HJ, Elias AD, Rugo HS, Cobleigh
MA, Wolff AC, Eisenberg PD, Lehman M, Adams BJ, Bello CL, DePrimo
SE, et al: Phase II study of sunitinib malate, an oral
multitargeted tyrosine kinase inhibitor, in patients with
metastatic breast cancer previously treated with an anthracycline
and a taxane. J Clin Oncol. 26:1810–1816. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hu N, Si Y, Yue J, Sun T, Wang X, Jia Z,
Gao S, Li Q, Shao Y, Wang J, et al: Anlotinib has good efficacy and
low toxicity: A phase II study of anlotinib in pre-treated HER-2
negative metastatic breast cancer. Cancer Biol Med. 18:849–859.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Li J, Qin S, Xu J, Xiong J, Wu C, Bai Y,
Liu W, Tong J, Liu Y, Xu R, et al: Randomized, double-blind,
placebo-controlled phase III trial of apatinib in patients with
chemotherapy-refractory advanced or metastatic adenocarcinoma of
the stomach or gastroesophageal junction. J Clin Oncol.
34:1448–14454. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hu X, Zhang J, Xu B, Jiang Z, Ragaz J,
Tong Z, Zhang Q, Wang X, Feng J, Pang D, et al: Multicenter phase
II study of apatinib, a novel VEGFR inhibitor in heavily pretreated
patients with metastatic triple-negative breast cancer. Int J
Cancer. 135:1961–1969. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hu X, Cao J, Hu W, Wu C, Pan Y, Cai L,
Tong Z, Wang S, Li J, Wang Z, et al: Multicenter phase II study of
apatinib in non-triple-negative metastatic breast cancer. BMC
Cancer. 14:8202014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhu A, Yuan P, Wang J, Fan Y, Luo Y, Cai
R, Zhang P, Li Q, Ma F and Xu B: Apatinib combined with
chemotherapy in patients with previously treated advanced breast
cancer: An observational study. Oncol Lett. 17:4768–4778.
2019.PubMed/NCBI
|
|
21
|
Patchell RA, Tibbs PA, Walsh JW, Dempsey
RJ, Maruyama Y, Kryscio RJ, Markesbery WR, Macdonald JS and Young
B: A randomized trial of surgery in the treatment of single
metastases to the brain. N Engl J Med. 322:494–500. 1990.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kalkanis SN, Kondziolka D, Gaspar LE,
Burri SH, Asher AL, Cobbs CS, Ammirati M, Robinson PD, Andrews DW,
Loeffler JS, et al: The role of surgical resection in the
management of newly diagnosed brain metastases: A systematic review
and evidence-based clinical practice guideline. J Neurooncol.
96:33–43. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Mills MN, Figura NB, Arrington JA, Yu HM,
Etame AB, Vogelbaum MA, Soliman H, Czerniecki BJ, Forsyth PA, Han
HS and Ahmed KA: Management of brain metastases in breast cancer: A
review of current practices and emerging treatments. Breast Cancer
Res Treat. 180:279–300. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Brown PD, Jaeckle K, Ballman KV, Farace E,
Cerhan JH, Anderson SK, Carrero XW, Barker FG II, Deming R, Burri
SH, et al: Effect of radiosurgery alone vs. radiosurgery with whole
brain radiation therapy on cognitive function in patients with 1 to
3 brain metastases: A randomized clinical trial. JAMA. 316:401–409.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Soffietti R, Abacioglu U, Baumert B, Combs
SE, Kinhult S, Kros JM, Marosi C, Metellus P, Radbruch A, Villa
Freixa SS, et al: Diagnosis and treatment of brain metastases from
solid tumors: Guidelines from the european association of
neuro-oncology (EANO). Neuro Oncol. 19:162–174. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Krop IE, Lin NU, Blackwell K, Guardino E,
Huober J, Lu M, Miles D, Samant M, Welslau M and Diéras V:
Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in
patients with HER2-positive metastatic breast cancer and central
nervous system metastases: A retrospective, exploratory analysis in
EMILIA. Ann Oncol. 26:113–119. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Jerusalem G, Park YH, Yamashita T, Hurvitz
SA, Modi S, Andre F, Krop IE, Gonzàlez Farré X, You B, Saura C, et
al: Trastuzumab deruxtecan in HER2-positive metastatic breast
cancer patients with brain metastases: A DESTINY-Breast01 subgroup
analysis. Cancer Discov. 12:2754–2762. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Alameddine RS, Otrock ZK, Awada A and
Shamseddine A: Crosstalk between HER2 signaling and angiogenesis in
breast cancer: Molecular basis, clinical applications and
challenges. Curr Opin Oncol. 25:313–324. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Nasir A, Holzer TR, Chen M, Man MZ and
Schade AE: Differential expression of VEGFR2 protein in HER2
positive primary human breast cancer: Potential relevance to
anti-angiogenic therapies. Cancer Cell Int. 17:562017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yen L, You XL, Al Moustafa AE, Batist G,
Hynes NE, Mader S, Meloche S and Alaoui-Jamali MA: Heregulin
selectively upregulates vascular endothelial growth factor
secretion in cancer cells and stimulates angiogenesis. Oncogene.
19:3460–3469. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Schwartzberg LS, Badarinath S, Keaton MR
and Childs BH: Phase II multicenter study of docetaxel and
bevacizumab with or without trastuzumab as first-line treatment for
patients with metastatic breast cancer. Clin Breast Cancer.
14:161–168. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lin NU, Seah DS, Gelman R, Desantis S,
Mayer EL, Isakoff S, Dipiro P, Krop IE, Come SE, Weckstein D, et
al: A phase II study of bevacizumab in combination with vinorelbine
and trastuzumab in HER2-positive metastatic breast cancer. Breast
Cancer Res Treat. 139:403–410. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Martin M, Makhson A, Gligorov J,
Lichinitser M, Lluch A, Semiglazov V, Scotto N, Mitchell L and
Tjulandin S: Phase II study of bevacizumab in combination with
trastuzumab and capecitabine as first-line treatment for
HER-2-positive locally recurrent or metastatic breast cancer.
Oncologist. 17:469–475. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Rugo HS, Chien AJ, Franco SX, Stopeck AT,
Glencer A, Lahiri S, Arbushites MC, Scott J, Park JW, Hudis C, et
al: A phase II study of lapatinib and bevacizumab as treatment for
HER2-overexpressing metastatic breast cancer. Breast Cancer Res
Treat. 134:13–20. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
He C, Cai P, Li J, Zhang T, Lin L, Abbasi
AZ, Henderson JT, Rauth AM and Wu XY: Blood-brain
barrier-penetrating amphiphilic polymer nanoparticles deliver
docetaxel for the treatment of brain metastases of triple negative
breast cancer. J Control Release. 246:98–109. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zhang H, Chen F, Wang Z and Wu S:
Successful treatment with apatinib for refractory recurrent
malignant gliomas: A case series. Onco Targets Ther. 10:837–845.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Song Y MD, PhD, Liu B MD, PhD; Guan M
Master of Medicine, ; Liu M: Successful treatment using apatinib in
intractable brain edema: A case report and literatures review.
Cancer Biol Ther. 19:1093–1096. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Hu T, Liu C, Li Q, Xiong J, Ma Y, Wu G and
Zhao Y: Apatinib + CPT-11 + S-1 for treatment of refractory brain
metastases in patient with triple-negative breast cancer: Case
report and literature review. Medicine (Baltimore). 97:e03492018.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Li T, Wang SB, Lei KJ, Jiang MQ and Jia
YM: Significant response of low-dose apatinib monotherapy in brain
metastases of triple-negative breast cancer: A case report.
Medicine (Baltimore). 98:e141822019. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Gradishar WJ, Tjulandin S, Davidson N,
Shaw H, Desai N, Bhar P, Hawkins M and O'Shaughnessy J: Phase III
trial of nanoparticle albumin-bound paclitaxel compared with
polyethylated castor oil-based paclitaxel in women with breast
cancer. J Clin Oncol. 23:7794–803. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Lin T, Zhao P, Jiang Y, Tang Y, Jin H, Pan
Z, He H, Yang VC and Huang Y: Blood-brain-barrier-penetrating
albumin nanoparticles for biomimetic drug delivery via
albumin-binding protein pathways for antiglioma therapy. ACS Nano.
10:9999–10012. 2016. View Article : Google Scholar : PubMed/NCBI
|
